Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

Phase 3

Active, not recruiting

Conditions: Childhood Malignant Liver Neoplasm
Hepatoblastoma
Fibrolamellar Carcinoma
Childhood Hepatocellular Carcinoma
Hepatocellular Malignant Neoplasm, Not Otherwise Specified

Interventions: Procedure: Biospecimen Collection
Other: Patient Observation
Drug: Cisplatin
Drug: Carboplatin
Procedure: Resection
Drug: Doxorubicin
Drug: Fluorouracil
Drug: Sorafenib
Drug: Gemcitabine
Drug: Vincristine Sulfate
Drug: Etoposide
Drug: Irinotecan
Drug: Oxaliplatin

First Posted Date: 2018-05-23

Last Posted Date: 2024-12-05

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 537

Registration Number: NCT03533582

Locations: 🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States

and more 202 locations

BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer

Phase 2

Terminated

Conditions: Cervical Cancer

Interventions: Drug: Nivolumab induction
Drug: Cisplatin
Radiation: Radiation
Drug: Nivolumab with chemoradiation
Drug: Nivolumab maintenance

First Posted Date: 2018-05-17

Last Posted Date: 2022-04-26

Lead Sponsor: Brown University

Target Recruit Count: 4

Registration Number: NCT03527264

Locations: 🇺🇸
Women and Infants Hospital, Providence, Rhode Island, United States
🇺🇸
Rhode Island Hospital, Providence, Rhode Island, United States

Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

Phase 2

Completed

Conditions: Urothelial Carcinoma
Kidney Cancer
Bladder Cancer
Ureter Cancer

Interventions: Other: Denosumab Placebo
Drug: Denosumab
Drug: Gemcitabine
Drug: Carboplatin
Drug: Cisplatin
Dietary Supplement: Calcium
Dietary Supplement: Vitamin D

First Posted Date: 2018-05-09

Last Posted Date: 2021-11-23

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 6

Registration Number: NCT03520231

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

Phase 3

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: pemetrexed
Biological: pembrolizumab
Drug: carboplatin
Drug: saline solution
Drug: cisplatin

First Posted Date: 2018-05-04

Last Posted Date: 2024-11-22

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 492

Registration Number: NCT03515837

Locations: 🇨🇳
Tangdu Hospital ( Site 0708), XI An, Shanxi, China
🇨🇳
Southwest Hospital, The Third Military Medical University ( Site 0725), Chongqing, Chongqing, China
🇨🇳
Henan Cancer Hospital ( Site 0711), Zhengzhou, Henan, China

and more 155 locations

Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC

Phase 3

Not yet recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: docetaxel, cisplatin, and fluorouracil
Drug: nedaplatin
Drug: docetaxel, nedaplatin, and capecitabine
Drug: cisplatin
Drug: docetaxel, cisplatin, and capecitabine
Drug: docetaxel, nedaplatin, and fluorouracil

First Posted Date: 2018-04-19

Last Posted Date: 2018-05-11

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 632

Registration Number: NCT03503136

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

Phase 2

Active, not recruiting

Conditions: Cancer of Unknown Primary Site

Interventions: Drug: Alectinib
Drug: Vismodegib
Drug: Carboplatin
Drug: Ipatasertib
Drug: Olaparib
Drug: Erlotinib
Drug: Cisplatin
Drug: Bevacizumab
Drug: Gemcitabine
Drug: Vemurafenib
Drug: Cobimetinib
Drug: Trastuzumab Subcutaneous (SC)
Drug: Pertuzumab
Drug: Atezolizumab
Drug: Paclitaxel
Drug: Entrectinib
Drug: Ivosidenib
Drug: Pemigatinib

First Posted Date: 2018-04-13

Last Posted Date: 2024-06-14

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 528

Registration Number: NCT03498521

Locations: 🇦🇺
Northern Cancer Institute, St Leonards, New South Wales, Australia
🇦🇺
Blacktown Hospital, Blacktown, New South Wales, Australia
🇫🇮
Helsinki University Central Hospital; Dept of Oncology, Helsinki, Finland

and more 134 locations

Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

Phase 2

Recruiting

Conditions: Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7
Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7

Interventions: Drug: Carboplatin
Drug: Cisplatin
Radiation: Image Guided Radiation Therapy
Drug: Docetaxel
Other: Laboratory Biomarker Analysis
Radiation: Intensity-Modulated Radiation Therapy
Other: Questionnaire Administration
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2018-04-10

Last Posted Date: 2024-12-24

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 82

Registration Number: NCT03493425

Locations: 🇺🇸
UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States
🇺🇸
UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida, United States
🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

and more 137 locations

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Phase 2

Recruiting

Conditions: Colorectal Neoplasms
Exocrine Pancreatic Cancer
Carcinoma, Non-Small-Cell Lung
Carcinoma, Squamous Cell of Head and Neck

Interventions: Drug: tisotumab vedotin
Drug: pembrolizumab
Drug: carboplatin
Drug: cisplatin

First Posted Date: 2018-04-02

Last Posted Date: 2024-11-13

Lead Sponsor: Seagen Inc.

Target Recruit Count: 692

Registration Number: NCT03485209

Locations: 🇺🇸
Shands Cancer Center / University of Florida, Gainesville, Florida, United States
🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

and more 69 locations

A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

Phase 1

Active, not recruiting

Conditions: Urothelial Carcinoma

Interventions: Drug: Erdafitinib
Drug: Cetrelimab
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2018-03-22

Last Posted Date: 2024-12-05

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 125

Registration Number: NCT03473743

Locations: 🇺🇸
Rocky Mountain Cancer Centers, Aurora, Colorado, United States
🇺🇸
Toledo Clinic Cancer Centers, Toledo, Ohio, United States
🇺🇸
Penn State Hershey Cancer Institute, Hershey, Pennsylvania, United States

and more 124 locations

Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients

Phase 2

Completed

Conditions: Gall Bladder Carcinoma
Cholangiocarcinoma Non-resectable
Gallbladder Carcinoma Non-Resectable
Cholangiocarcinoma

Interventions: Biological: Durvalumab
Drug: Gemcitabine
Drug: Cisplatin
Biological: Tremelimumab

First Posted Date: 2018-03-22

Last Posted Date: 2023-06-15

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 128

Registration Number: NCT03473574

Locations: 🇩🇪
Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie & Endokrinologie, Hannover, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy